Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $55.4 million.

  • Aclaris Therapeutics' Total Liabilities rose 610.8% to $55.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.4 million, marking a year-over-year increase of 610.8%. This contributed to the annual value of $64.8 million for FY2024, which is 6102.27% up from last year.
  • According to the latest figures from Q3 2025, Aclaris Therapeutics' Total Liabilities is $55.4 million, which was up 610.8% from $57.4 million recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Total Liabilities high stood at $64.8 million for Q4 2024, and its period low was $27.2 million during Q2 2024.
  • For the 5-year period, Aclaris Therapeutics' Total Liabilities averaged around $50.1 million, with its median value being $52.9 million (2023).
  • As far as peak fluctuations go, Aclaris Therapeutics' Total Liabilities tumbled by 5125.32% in 2024, and later soared by 11067.93% in 2025.
  • Aclaris Therapeutics' Total Liabilities (Quarter) stood at $53.9 million in 2021, then grew by 5.76% to $57.0 million in 2022, then fell by 29.4% to $40.2 million in 2023, then skyrocketed by 61.02% to $64.8 million in 2024, then decreased by 14.42% to $55.4 million in 2025.
  • Its Total Liabilities stands at $55.4 million for Q3 2025, versus $57.4 million for Q2 2025 and $54.0 million for Q1 2025.